Lauren E. Intravaia

Lauren E. Intravaia

Auto-generated profile, based on publicly available information

Lauren E. Intravaia

Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, United States

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2026 in Science Advances
Verified
Journal Article
Open access
SDSarah N Zvornicanin, Duggan
Sarah N Zvornicanin, Duggan
ASAla M Shaqra
Ala M Shaqra
JFJulia Flynn
Julia Flynn
LILauren E. Intravaia
Lauren E. Intravaia
HMHeidi Carias Martinez
Heidi Carias Martinez
NYNese Kurt Yilmaz
Nese Kurt Yilmaz
The coronaviral main protease (M pro ) has been the subject of various biochemical and structural studies and a drug target against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. SARS-CoV-2 M pro is active as a dimer, but despite apparent cooperativity in catalytic activity, how the two distal active sites communicate and modulate binding and/or catalysis is unclear. Here, we have investigated the interplay between cooperativity, dimerization, and substrate cleavage in SARS-CoV-2 M pro through a combination of enzymatic assays, crystal structures, and protein characterization. To disentangle the contribution of each active site to the observed enzymatic activity, we developed a cleavage assay involving heterodimers of active and inactive (catalytic residue mutated or inhibitor-bound) monomers. Notably, we found that heterodimerization increased cleavage efficiency per active monomer. In addition, we mapped a network of critical residues bridging the two active sites and probed this network through engineered mutations. By dissecting the cooperativity and communication between the active sites, we provide insights into the M pro reaction cycle and functional significance of its dimeric architecture.

29 August 2026 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Leonard BarasaLeonard Barasa
Leonard Barasa
YCYongzhi Chen
Yongzhi Chen
ASAla M. Shaqra
Ala M. Shaqra
SASyeda F. Z. Adnan
Syeda F. Z. Adnan
LILauren E. Intravaia
Lauren E. Intravaia
PTPaul R. Thompson
Paul R. Thompson

1 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
LILauren E. Intravaia
Lauren E. Intravaia
JKJagroop Kaur
Jagroop Kaur
ASAla M Shaqra
Ala M Shaqra
MHMina Henes
Mina Henes
KKKlajdi Kosovrasti
Klajdi Kosovrasti
CSCelia Schiffer
Celia Schiffer
Drug resistance often emerges through mutations that reshape protein conformational ensembles, allowing inhibitor potency to be altered without directly disrupting protein-ligand contacts. Consequently, the molecular mechanisms underlying these effects remain difficult to identify, hindering the design of inhibitors with durable potency against rapidly evolving drug targets. To address this challenge, we developed ROBUST, a physics-informed machine learning framework that integrates experimental measurements, molecular dynamics simulations, and interpretable statistical modeling to identify energetic determinants of inhibitor potency. Using HIV-1 protease as a stringent model system for drug resistance, we determined 157 new inhibition constants and integrated them with prior measurements to establish a comprehensive experimental dataset of 364 protease-inhibitor pairs. Analysis of the corresponding molecular dynamics simulations revealed a compact network of energetic interactions that quantitatively explains how resistance mutations and inhibitor modifications jointly reshape molecular recognition and inhibitor potency across the multidimensional resistance landscape. Models constructed from these energetic signatures predicted binding free energies with high accuracy (RMSE < 1 kcal mol −1 ) and successfully generalized to unseen darunavir analogs. Importantly, ROBUST accurately prioritized unseen analogs based on their potency across the variant set, demonstrating its utility for identifying compounds with improved resistance profiles. Together, these results uncover the energetic principles through which resistance mutations and inhibitor modifications alter potency and establish ROBUST as a mechanistically interpretable framework for translating these insights into resistance-aware inhibitor optimization against rapidly evolving drug targets.